✦ LIBER ✦

POST-CHEMOTHERAPY RETROPERITONEAL LYMPH NODE DISSECTION CAN NOT BE SAFELY OMITTED IN PATIENTS WITH METASTATIC NON-SEMINOMATOUS GERM CELL TESTIS CANCER

✍ Scribed by Nguyen, Carvell T; Subramanian, Vairavan S; Stephenson, Andrew J; Klein, Eric A

Book ID: 122928661
Publisher: Lippincott Williams and Wilkins
Year: 2008
Tongue: English
Weight: 124 KB
Volume: 179
Category: Article
ISSN: 0022-5347
DOI: 10.1016/S0022-5347(08)60511-X

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

RAPIDLY ALTERNATING, DOSE-DENSE CHEMOTHE

RAPIDLY ALTERNATING, DOSE-DENSE CHEMOTHERAPY AND RETROPERITONEAL LYMPH NODE DISSECTION (RPLND): OUTCOMES IN PATIENTS WITH HIGH-RISK NON-SEMINOMATOUS GERM CELL TUMOR

✍ Kim, Philip H; Syan, Sumeet K.; Dorff, Tanya B.; Quinn, David; Skinner, Donald G 📂 Article 📅 2009 🏛 Lippincott Williams and Wilkins 🌐 English ⚖ 49 KB

RANDOMISED PHASE III TRIAL COMPARING RET

RANDOMISED PHASE III TRIAL COMPARING RETROPERITONEAL LYMPH NODE DISSECTION (RPLND) WITH ONE COURSE OF BLEOMYCIN, ETOPOSIDE, CISPLATIN (BEP) CHEMOTHERAPY IN PATIENTS WITH STAGE I NON-SEMINOMATOUS GERM CELL TUMOUR PATIENTS (NSGCT) – UPDATED RESULTS OF AUO TRIAL 01/94

✍ P. Albers; R. Siener; S. Krege; H.U. Schmelz; K.P. Dieckmann; A. Heidenreich; P. 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 69 KB